Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Operating Income Loss of $340.99 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +13,508.9% in Operating Income Loss from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), BIOCRYST PHARMACEUTICALS INC's Operating Income Loss has grown by 2,582.3%.
- Historical annual values: Fiscal year 2025: $340.99 million | Fiscal year 2024: -$2.54 million | Fiscal year 2023: -$103.71 million | Fiscal year 2022: -$148.44 million | Fiscal year 2021: -$177.72 million | Fiscal year 2020: -$174.76 million | Fiscal year 2019: -$99.46 million | Fiscal year 2018: -$94.22 million | Fiscal year 2017: -$57.41 million | Fiscal year 2016: -$48.61 million | Fiscal year 2015: -$39.44 million | Fiscal year 2014: -$45.77 million | Fiscal year 2013: -$30.72 million | Fiscal year 2012: -$33.89 million | Fiscal year 2011: -$49.59 million | Fiscal year 2010: -$34.36 million | Fiscal year 2009: -$13.74 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: